期刊
RHEUMATOLOGY
卷 59, 期 -, 页码 I37-I46出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kez383
关键词
psoriatic arthritis; therapy; treatment guidelines; treat-to-target; outcomes
类别
资金
- National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
- Novartis
Psoriatic arthritis (PsA) is a complex inflammatory musculoskeletal and skin disease. The treatment of PsA has changed substantially over the past 10 years. Clinical practice guidelines are developed to help busy clinicians rapidly integrate evolving knowledge of therapeutic management into practice. In this review, we compare PsA treatment recommendations or guidelines developed by one national organization [ACR and National Psoriasis Foundation (NPF) in 2018], one regional organization (EULAR in 2015), and one international organization (the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis in 2015). We examine the development of guidelines in PsA more broadly and examine similarities and differences in the three sets of recommendations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据